Two novel cases further expand the phenotype of TOR1AIP1-associated nuclear envelopathies

Ivana Lessel1 · Mei-Jan Chen2 · Sabine Lüttgen1 · Florian Arndt3 · Sigrid Fuchs1 · Stefanie Meien1 · Holger Thiele4 · Julie R. Jones5 · Brandon R. Shaw2 · David K. Crossman2 · Peter Nürnberg4,6,7 · Bruce R. Korf2 · Christian Kubisch1 · Davor Lessel1

Received: 2 November 2019 / Accepted: 22 December 2019 / Published online: 13 February 2020
© The Author(s) 2020

Abstract
Biallelic variants in TOR1AIP1, encoding the integral nuclear membrane protein LAP1 (lamina-associated polypeptide 1) with two functional isoforms LAP1B and LAP1C, have initially been linked to muscular dystrophies with variable cardiac and neurological impairment. Furthermore, a recurrent homozygous nonsense alteration, resulting in loss of both LAP1 isoforms, was identified in seven likely related individuals affected by multisystem anomalies with progeroid-like appearance and lethality within the 1st decade of life. Here, we have identified compound heterozygosity in TOR1AIP1 affecting both LAP1 isoforms in two unrelated individuals affected by congenital bilateral hearing loss, ventricular septal defect, bilateral cataracts, mild to moderate developmental delay, microcephaly, mandibular hypoplasia, short stature, progressive muscular atrophy, joint contractures and severe chronic heart failure, with much longer survival. Cellular characterization of primary fibroblasts of one affected individual revealed absence of both LAP1B and LAP1C, constitutively low lamin A/C levels, aberrant nuclear morphology including nuclear cytoplasmic channels, and premature senescence, comparable to findings in other progeroid forms of nuclear envelopathies. We additionally observed an abnormal activation of the extracellular signal-regulated kinase 1/2 (ERK 1/2). Ectopic expression of wild-type TOR1AIP1 mitigated these cellular phenotypes, providing further evidence for the causal role of identified genetic variants. Altogether, we thus further expand the TOR1AIP1-associated phenotype by identifying individuals with biallelic loss-of-function variants who survived beyond the 1st decade of life and reveal novel molecular consequences underlying the TOR1AIP1-associated disorders.

Introduction
Nuclear envelopathies, caused by pathogenic variants in genes that encode proteins of the nuclear envelope, are a group of genetic disorders with remarkable clinical and genetic heterogeneity (Nagano and Arahata 2000). Several such genes have been connected with human diseases displaying a wide variety of clinical symptoms, including muscular dystrophies, cardiomyopathies, lipodystrophies, skeletal anomalies, anomalies of the skin, cataracts, neuropathies, leukodystrophies, Pelger–Huet anomaly, and progeroid features. Examples include LMNA (MIM: 150330) (Alastalo et al. 2015; Bonne et al. 1999; Cao and Hegele

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00439-019-02105-6) contains supplementary material, which is available to authorized users.

1 Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
2 Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 36394, USA
3 Department for Pediatric Cardiology, University Heart Center Hamburg, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
4 Cologne Center for Genomics, University of Cologne, 50931 Cologne, Germany
5 Molecular Diagnostic Laboratory, Greenwood Genetic Center, Greenwood, SC 29646, USA
6 Center for Molecular Medicine Cologne, University of Cologne, 50931 Cologne, Germany
7 Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, 50931 Cologne, Germany
The most heterogeneous group among nuclear envel-
opathies is due to mutations in LMNA, encoding A and C
lamin. Alterations in LMNA can result in Emery–Dreifuss
muscular dystrophy (MIM: 165166 and 181350) (Bon
ne et al. 1999), limb girdle muscular dystrophy 1B (MIM:
159001) (Muchir et al. 2000), congenital muscular dystrophy
(MIM: 613205) (Quijano-Roy et al. 2008), dilated cardio-
myopathy with conduction system defects (MIM: 115200)
(Fatkin et al. 1999), autosomal recessive forms of axonal
Charcot–Marie–Tooth (MIM: 605588) (De Sandre-Gio-
vanni et al. 2002), restrictive dermopathy (MIM: 275210)
(Navarro et al. 2004), LEMD2 (MIM: 616312) (Boone et
al. 2015), LEMD3 (MIM: 607844) (Hellemans et al. 2004), and BANFI (MIM: 603811) (Puente et al. 2011).

In addition to the genes named above, biallelic patho-
genic variants in TOR1AIP1 (MIM: 614512), encoding the
integral nuclear membrane protein LAP1 (lamina-associated
polypeptide 1), have been described in a family with three
individuals affected by muscular dystrophy with variable
cardiac involvement (Kaynan-Kurekci et al. 2014), in a boy
affected by dystonia, cerebellar atrophy, and cardiomyopathy
(Dorboz et al. 2014), and in two siblings affected by cardiac
involvement (Kayman-Kurekci et al. 2014), in a boy
affected by multisystem anomalies and progeroid appearance
that progressed with age. Moreover, we present the cellular
characterization of primary fibroblasts of one of the affected
individuals.

Materials and methods

Human subjects

All biological samples were obtained after written informed
consent. The study was performed in accordance with the
Declaration of Helsinki protocols and approved by the ethics
committee of the respective institution.

Cell lines

Primary human dermal fibroblast cultures were established
from skin biopsies taken from the patient and three healthy
donors (aged of 26, 34 and 35, respectively). Cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM),
supplemented with 10% fetal bovine serum (Life Tech-
ologies, 10270-106), 1% amphotericin B solution (Sigma,
A2942) and 1% penicillin–streptomycin solution (Sigma,
P4333) under 5% CO₂ and at 37 °C. For all experiments,
cells were trypsinized with trypsin–EDTA solution (Sigma,
T3924) and seeded 24 h prior to the beginning of the
experiment.

Genetic analyses

DNA samples from whole blood were isolated by stand-
ard procedures. Exome sequencing of the proband 1 was
performed using an Illumina GAIIx Sequencer with the
Agilent SureSelect Human All Exon 50 Mb kit, as previ-
ously described (Lesse et al. 2014a). Approximately, 95%
of target sequences covered at least tenfold and 89% 30-fold,
with a mean coverage of 109x. Individual 2 was sequenced
with the Agilent SureSelect Human All Exon V5 kit. The
targeted regions were sequenced using the Illumina Next-
Seq 500 System with 150 bp paired-end reads. Following
Broad’s Genome Analysis Toolkit (GATK) Best Practices
guidelines, the DNA sequence was aligned and compared
to the human genome build 19 (hg19/NCBI build 37). The
average depth of coverage was 170x. The Cartagenia Bench
Lab NGS software was used to filter and analyze sequence
variants identified in the patient and compare them to the
sequences of proband’s mother and sister. PCR and Sanger
sequencing were performed as described previously (Lesse
et al. 2015). All primer pairs are available upon request.
Western blot analysis

Primary fibroblasts were lysed with protein lysis buffer containing 10 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 10% glycerol, 10% proteinase inhibitors cocktail (Roche, 11 836 153 001) and 1 mM DTT. Total cell protein was obtained after 30 min of centrifugation (16,000 rpm). Protein concentration was determined with PierceTM BCA protein assay kit (Thermo Scientific, 23227) according to manufacturer’s instructions by reading absorbance at 562 nm with Epoch microplate spectrophotometer (BioTek). Protein volumes were adjusted to bring equal amounts on gel, mixed with BoltTM LDS sample buffer (Life Technologies, B0007) and BoltTM sample reducing agent (Life Technologies, B0009) according to manufacturer’s instructions. Afterwards, the samples were denaturated at 70 °C for 10 min and transferred to Bolt 4–12% Bis–Tris Plus Gel (Life Technologies, NW04120BOX). Samples were run at 165 V for 45 min in BoltTM MOPS SDS running buffer (Life Technologies, B0001). Proteins were transferred to the nitrocellulose membrane (Life Technologies, LC2000) at 10 V for 1 h and 15 min using Mini Blot Module (Life Technologies, B1000) and Bolt transfer buffer (Life technologies, BT0006) according to manufacturer’s instructions.

Immunofluorescence

Primary fibroblasts were grown on glass coverslips, fixed with 4% formaldehyde, permeabilized with 0.1% Triton X-100, 0.1% Na citrate, blocked with 5% BSA in PBS and immunostained with the respective antibodies which were diluted in 5% BSA in PBS. Images were taken using Axioplan 2 imaging microscope (Zeiss, Jena, Germany) and captured using the AxioVision Imaging System (Zeiss, Jena, Germany). Nuclear abnormalities were estimated directly by visual observation at 100× magnification, in at least 100 cells per experiment.

Antibodies

Primary antibodies used in this study were anti-beta actin (Abcam, ab8224), anti-ERK1/2 (Cell Signaling, 9102), anti-phospho ERK1/2 (Cell Signaling, 9101), anti-lamin A/C (Santa Cruz, sc-7292), anti-lamin B1 (Santa Cruz, sc-30264), anti-S6 kinase (Cell Signaling, 2317), anti-phospho S6 kinase (Cell Signaling, 2211) and anti-LAP1 (Atlas antibodies, HPA050546).

Senescence-associated β-galactosidase activity assay

Cells were seeded for 24 h and the endogenous mammalian senescence-associated β-galactosidase activity (SAβ-gal) was evaluated using the Senescence β-Galactosidase Staining Kit (Cell Signaling), according to the manufacturer’s guidelines as previously described (Lessel et al. 2017b).

Cell transfection with plasmid DNA

Plasmid-encoding Myc-Flag-tagged TOR1AIP1 (Origene, RC221686) was used in all experiments. 70,000 cells were seeded on 6-well cell culture plates for 24 h to ensure ~70% confluent cultures 24 h after seeding. 4 µg of plasmid DNA was transfected for additional 24 h using the Viromer Red reagent according to manufacturer’s instructions (Lipocalyx, Halle, Germany).

RNA isolation and quantitative real-time PCR (qRT-PCR)

Total RNA was extracted with the RNaseasy mini kit (Qiagen) from primary fibroblasts that were in all in the same passage 8, and qRT-PCR with TaqMan probes was performed as previously described (Lessel et al. 2017a). TaqMan Gene Expression Assays (ThermoFisher Scientific) for the following human genes were used: TOR1AIP1 (Assay ID: Hs01042342_m1), LMNA (Assay ID: Hs00153462_m1), LMNB1 (Assay ID: Hs01059203_m1) and GAPDH (Assay ID: Hs02786624_g1).

Statistical analysis

All analyses were performed using Prism 6 (GraphPad). Significance was determined with two-tailed Student’s t test. P values less than 0.05 were considered significant. Data represent mean ± SEM.

Results

Case reports

Individual 1 is a 34-year-old male who has since birth been regularly followed up at the University Medical Center Hamburg-Eppendorf. He is the first child of two, and his unaffected unrelated parents are of European descent. His 30-year-old brother is unaffected. Due to oligohydramnios, he was born at 34 weeks of gestation with a birth weight of 1940 g (− 0.95 SD), length of 40 cm (− 2.14 SD) and an occipitofrontal head circumference (OFC) of 31 cm (− 0.71 SD). Postnatal echocardiography revealed a ventricular septal defect (VSD) that spontaneously closed before his first birthday. In addition, hypospadias, undescended testes and congenital bilateral sensorineural hearing loss were diagnosed. Motor development was unaffected, with rolling over at 7 months and walking at 12 months. At the visit at the age...
of 8 years, we noted short stature and microcephaly [height 116.5 cm (−2.43 SD) and OFC 48 cm (−3.73 SD)]. We observed facial dysmorphisms that included long eyelashes, swinging eyebrows, telecanthus, epicanthus, antverted nostrils, a long philtrum, and mandibular hypoplasia with dental crowding and irregular teeth. He had thin hair and developed bilateral cataracts and a mild hepatosplenomegaly. Further, a delay in speech development was noted, which was at that time regarded as a consequence of bilateral hearing loss. Extensive metabolic studies, bone age assessment and brain CT yielded normal results. EEG revealed a mild increase in cerebral excitability. Conventional chromosome analysis in lymphocytes gave normal results. Since his late 20s, he has had repeatedly elevated non-fasting glucose levels ranging from 127 to 201 mg/dl (reference 60–110 mg/dl), suggestive of type 2 diabetes; however, due to the lack of compliance, confirmatory tests have not been performed. In addition, he has had repeatedly elevated blood levels of non-fasting cholesterol ranging from 205 to 220 mg/dl (reference 150–200 mg/dl), ALT ranging from 320 to 480 U/l (reference 87–241 U/l), GGT ranging from 72 to 150 U/l (reference <65 U/l), and creatinine ranging from 1.64 to 3.60 mg/dl (reference 0.6–1.2 mg/dl). At the visit at the age of 31 years, he presented with bilateral hearing loss, mandibular hypoplasia with dental crowding and irregular teeth, scleroderma-like skin changes, Raynaud’s phenomenon, hand joint contractures, mild intellectual disability, muscular atrophy and proximal muscle weakness, dilated cardiomyopathy and chronic heart failure with significant reduction of left ventricular ejection fraction of 35% (normal range 50–70%) (Fig. S1). His weight was 40 kg and height 157 cm, resulting in a BMI of 16.23 kg/m². The height of his mother, father and unaffected brother were 156 cm, 178 cm and 176 cm, respectively. His speech was slurred, although he had good speech understanding. Taken together, the combination of his symptoms led to the clinical diagnosis of a segmental progeroid syndrome. At the age of 32 years, following acute pneumonia, he experienced a fulminant cardiac crisis. In more detail, a cardiac decompensation with ventricular fibrillation occurred that required a short-term resuscitation including defibrillation. As a result, he developed acute renal failure with the need to start dialysis. An implantable cardioverter defibrillator (ICD) and an atrial (Demers) catheter for hemodialysis were implanted (Fig. S1b), followed by intensified anticongestive and anti-arrhythmic therapy. Currently, at the age of 34 years, he still has severely reduced left ventricular function, receives dialysis for chronic renal failure, and experiences increasing difficulties in climbing stairs. Regarding diagnostic genetic analysis, chromosome analyses in blood lymphocytes did not demonstrate spontaneous chromosomal instability or hypersensitivity towards the genotoxic agent mitomycin C. Array CGH, and direct sequencing of WRN, POLD1 and LMNA all gave normal results.

Individual 2 was a 16-year-old white male born after a full-term uncomplicated pregnancy to a 34-year-old G3P3 mother with birth weight of 3700 g. Both parents were unaffected and unrelated. His two siblings, age 17 and 15, respectively, were also healthy. A profound congenital sensorineural hearing loss was found at newborn screening. At 1 week of age, VSD was diagnosed, as well as an asymptomatic bicuspid pulmonary valve and persistence of a dilated pulmonary artery. The VSD was eventually closed. At 1.5 months of age, he developed bilateral cataracts and underwent surgical lens implants. He had G-tube insertion in early childhood due to feeding difficulty and failure to thrive. At his 4.5-year-old visit, he was noted to have microcephaly and short stature [OFC 47 cm (−2.30 SD) and height 99 cm (−1.74 SD)]. Other dysmorphic features included low-set and posteriorly rotated ears, deep-set eyes, thin nose, high-arched palate, long philtrum, thin upper lip, down-turned mouth, mandibular hypoplasia, and dental crowding. His development was globally delayed; he walked at 2.5 years, was nonverbal, but had learned 100–200 signs. There was no evidence of deterioration until he was around 11 years of age. At age 12, he developed bilateral ptosis, horizontal nystagmus, swallowing dysfunction, hypotonia, muscle weakness, gait changes, asymmetric and small thoracic size, mixed pectus carinatum and pectus excavatum, kyphoscoliosis, femoral anteverision, and cardiac arrhythmia. He had G-tube re-insertion due to difficulty swallowing. He also had surgery for bilateral ptosis and dental abnormalities. His symptoms continued to progress and at 15 years he was diagnosed with dilated cardiomyopathy with moderate left ventricular dysfunction. His left ventricular ejection fraction was 35.1% (normal range 50–70%) and frequent (2.2% of time) ventricular ectopic activity was detected through a 24-h Holter electrocardiogram (Fig. S2). At a clinical visit at age 16, he had chronic heart failure with ejection fraction only at 39%. He was mostly wheelchair-bound with global hypotonia and muscle weakness. Joint contractures were observed in his elbows, wrists, fingers and lower extremities. He also had nearly constant choreoathetoid movements and dystonic posture. His height was 149.8 cm (−3.58 SD), weight 30.6 kg (−5.17 SD) and head circumference 50 cm (−4.27 SD). He died at age 16 years due to progressive heart failure. Quadriiceps muscle biopsy at 1.5 years of age showed variable myofiber size with occasional small atrophic myofibers and centrally positioned nuclei; these findings were not considered specific for any specific disease processes. At the age of 12 years, brain MRI showed minimal periventricular signal abnormality but was otherwise within normal limits. CPK level was slightly decreased at 45 (normal: 55–215) and lactic acid was slightly elevated at 22.6 (normal: 4.5–18). Extensive metabolic and biochemical
workup was unrevealing, including plasma amino acids, acylcarnitine, carnitine, GALT, urine amino acids, organic acids, MPS type 1, GAG, lysosomal enzyme, carbohydrate deficient transferrin, N-glycan, O-glycan, 7-dehydrocholesterol, and very-long-chain fatty acids. Negative genetic testing included FISH, karyotype, mitochondrial DNA genome sequence, cytogenomic microarray, and direct sequencing of GJB2, GJB6, SLC52A3, SLC52A2, and SLC52A1.

Taken together, both individuals presented with congenital bilateral hearing loss and ventricular septal defect, followed by development of bilateral cataracts, mild to moderate developmental delay, microcephaly, mandibular hypoplasia with dental crowding and irregular teeth, relative short stature, progressive muscular atrophy, joint contractures, dilated cardiomyopathy, and reduced left ventricular ejection fraction followed by severe chronic heart failure (Fig. 1, Table 1, Fig. S1 and S2). Thus, both prematurely developed a combination of symptoms commonly observed in the elderly, i.e., bilateral cataracts, progressive muscular atrophy and early onset cardiomyopathy, similar to the findings in diverse segmental progeroid syndromes (Lessel and Kubisch 2019; Martin 1978, 2005).

Genetic analyses

To identify the putative genetic cause, whole-exome sequencing (WES) was performed with DNA samples of both affected individuals. Bioinformatic filtering of WES data in individual 1 for putatively de novo variants detected 42 heterozygous alterations that have previously not been annotated in dbSNP, the ExAC database or the 1000 Genomes data; however, subsequent Sanger sequencing with DNA samples of both healthy parents and individual 1 revealed that each of these variants was inherited (Table S1). Further, we did not detect rare candidate variants (minor allele frequency MAF < 0.001) following an X-linked recessive mode of inheritance or any putatively pathogenic homozygous alterations. However, we identified two genes with rare (minor allele frequency MAF < 0.001) double heterozygous variants affecting GMPPA and TOR1AIP1 (Table S2). Segregation analysis revealed that both heterozygous variants affecting GMPPA were inherited from the unaffected father, thus excluding a causative role. On the contrary, we confirmed a paternally inherited c.945_948delCAGT, p.(Gln315His fs*9), and a maternally inherited c.1331G > C, p.(Arg444Pro), mutation in TOR1AIP1 (NM_001267578.1) (Fig. 2a). The frameshift variant is predicted to lead to a premature termination codon, likely activating nonsense-mediated mRNA decay. The arginine residue at position 444 is highly conserved in LAP1 orthologues; accordingly, p.(Arg444Pro) is classified as “probably damaging” with a maximum score of 1.0.

Fig. 1 Facial and body images of the here presented individuals. Images of individual 1 at the ages of 2 years, 8 years and 31/32 years. Note the small chin and dental crowding indicative for mandibular hypoplasia (a). Images of individual 2 at 16 years (b)
by Polyphen-2. It also has a very high phred-scaled CADD (v1.3) score of 29.6, consistent with a pathogenic variant.

Bioinformatic filtering of WES data in individual 2 also revealed two likely pathogenic variants in TOR1AIP1, namely, a maternally inherited variant c.724delG, p.(Asp242Ile*17) and a second heterozygous variant c.649G>T, p.(Glu217*). As paternal DNA was not available for sequencing, we could only infer that this second variant is likely to have been inherited from his father, as it is absent in both his mother and unaffected sister. His unaffected sister

Table 1  Clinical characteristics of individuals with TOR1AIP1 variants

| Reference | Individual 1 of this article | Individual 2 of this article | Kayman-Kurekci et al. | Dorboz et al. | Ghaoui et al. | Fichtman et al. |
|-----------|------------------------------|-----------------------------|-----------------------|---------------|---------------|-----------------|
| Number of subjects | +                            | 1                           | 3                     | 1             | 2             | 7               |
| Congenital heart defect | +                            | +                           | −                     | −             | −             | 6/7             |
| Hearing loss | Congenital                    | Congenital                  | −                     | −             | −             | 7/7, congenital 3/7 |
| Mandibular hypoplasia | +                            | +                           | *                     | −             | −             | −               |
| Bilateral cataracts | +                            | +                           | −                     | −             | −             | 7/7             |
| Developmental delay | Mild                         | Moderate                    | −                     | −             | −             | 1/2 Severe 7/7  |
| Short stature | +                            | +                           | *                     | −             | −             | −               |
| Microcephaly | +                            | +                           | −                     | −             | −             | 7/7             |
| Joint contractures | +                            | +                           | 3/3                   | −             | −             | 0/7             |
| Muscle weakness | +                            | +                           | 3/3                   | −             | −             | 2/2 7/7         |
| Dilated cardiomyopathy | +                           | +                           | 1/2                   | +             | −             | 2/2 ?           |
| Chronic heart failure | +                            | +                           | −                     | −             | +             | 2/2 ?           |
| Skin manifestations | Scleroderma-like skin changes | −                           | −                     | −             | −             | −               |
| Raynaud’s phenomenon | +                            | −                           | −                     | −             | −             | −               |
| Feeding difficulties | +                            | +                           | ?                     | ?             | ?             | −               |
| Gastrointestinal anomalies | −                            | −                           | ?                     | ?             | ?             | 5/7             |
| Renal anomalies | +                            | −                           | −                     | −             | +             | −               |
| Dystonia | −                            | −                           | −                     | −             | −             | −               |
| Brain MRI/CT | Normal results               | Minimal periventricular signal abnormality | −?                    | Cerebellar atrophy | Normal results | Global parenchymal brain atrophy 4/4 |
| TOR1AIP1 mutations | c.945_948delCAGT/c.1331G>C | c.649G>T/c.724delG | p.(Glu217*)/p.(Asp242Ile*17) | c.1448A>T/c.1448A>T | p.Glu482Ala/p.Glu482Ala | c.961C>T/c.961C>T |
|                  | c.127delC/c.1181T>C          | c.186delG/c.186delG           | p.Glu482Ala/p.Glu482Ala | c.127delC/c.1181T>C | p.Pro436*15/p.Leu394Pro | p.Arg321*/p.Arg321* |

+, Present; −, absent; *not reported in the manuscript, however, observed to be presented in Fig. 1b (Kayman-Kurekci et al. 2014); ?, not reported.
is a carrier of the c.724delG, p.(Asp242Ilefs*17) (Fig. 2b). Similar to the p.(Gln315Hisfs*9), these frameshift and nonsense variants are predicted to lead to a premature termination codon, likely activating nonsense-mediated mRNA decay as was recently shown for the homozygous p.(Arg321*). According to the gnomAD database, all four identified variants are exceedingly rare: p.(Glu217*) was observed 3 times, p.(Asp242Ilefs*17) was observed 1 time, p.(Arg444Pro) was observed 16 times, whereas p.(Gln315Hisfs*9) was not annotated in this database. Taken together, the genetic data provided strong support for the causality of these TOR1AIP1 variants.

**Low protein levels of LAP1B/LAP1C accompanied by low protein and mRNA levels of lamin A/C and lamin B1 in dermal fibroblasts of individual 1**

To corroborate our genetic findings and provide further evidence for the causality of the TOR1AIP1 variants identified in individual 1, we established primary dermal fibroblasts
of individual 1. We additionally established primary dermal fibroblasts of three unaffected individuals of similar age (controls 1–3, aged 26, 34 and 35, respectively). Individual 2 unfortunately deceased prior to skin biopsy, thus we were unable to analyze his primary cell lines. It is, however, worth noting that both of the variants identified in individual 2 lead to premature stop codons which are more N-terminal than the p.(Arg321*), for which a nonsense-mediated mRNA decay was recently shown (Fichtman et al. 2019). Given that the individuals bearing the homozygous p.(Arg321*) show a complete loss of both LAP1 protein isoforms, LAP1B and LAP1C, by immunoblotting, we first analyzed these isoforms in individual 1. Surprisingly, given that individual 1 survived far longer and that he bears a missense variant in addition to a frameshift one, we were not able to detect either LAP1B or LAP1C in any of the four subsequent passages (passages 4–7). In contrast, both LAP1B and LAP1C were detected in control fibroblasts (Fig. 3a, Fig. S3). Quantitative real-time PCR (qRT-PCR) did not reveal a difference in the mRNA level between individual 1 and two controls (Fig. 3b). However, structure- and sequence-based predictors of the effect of single point variations on protein stability I-Mutant v2.0 (Capriotti et al. 2005), iPTREE-STAB (Huang et al. 2007), Site Directed Mutator (Pandurangan et al. 2017) and Cupsat (Parthiban et al. 2006) all predicted a large decrease in stability, suggesting that the p.Arg444Pro results in an unstable protein.

We next analyzed protein levels of two proteins within the nuclear lamina which support the inner nuclear membrane, lamin B1 and lamin A/C, in three subsequent passages (passages 4–6) of individual 1 fibroblasts and fibroblasts from an unaffected control individual. We observed, relative to fibroblasts from the healthy control individual, lower levels of lamin B1 (Fig. 3c, d, Fig. S4) and very low basal levels of both lamins A and C, even after prolonged exposure (Fig. S5). Given that previous studies did not reveal reduced lamin A/C levels (Fichtman et al. 2019; Ghaoui et al. 2016), we additionally analyzed lamin A and C levels in primary fibroblasts of two further independent unaffected individuals and observed again much lower levels of lamins A and C (Fig. 3f). Similarly, qRT-PCR analyses revealed significant reduction of LMNA and LMNB1 in the mRNA level (Fig. 3e, g). Thus, our data provide further evidence for LAP1 involvement in the regulation of lamins, exemplifying the complexity of the interconnected nuclear membrane system.

**Nuclear abnormalities in patient’s dermal fibroblasts**

Given the role of LAP1B in the maintenance of nuclear membrane morphology (Kim et al. 2010; Serrano et al. 2016) and previous findings in individuals affected by a TORIAIP1-associated disorder (Fichtman et al. 2019; Kayman-Kurekci et al. 2014), we performed immunofluorescence analysis of fibroblasts derived from individual 1 and an unaffected control individual. In control fibroblasts, all cells displayed positive lamin A/C staining, and the majority, around 90%, of nuclei were oval or ovoid (Fig. 4a). On the contrary and in line with reduced lamin A/C protein levels, in fibroblasts of individual 1, we observed loss of lamin A/C staining in roughly 18% of analyzed nuclei (Fig. 4b), which was not observed in control fibroblasts. These findings are comparable to the observed effect in primary fibroblasts of individuals bearing the homozygous p.Arg321* variant that also displayed reduced lamin A/C staining (Fichtman et al. 2019). Further, we observed invagination of the nuclear envelope (Fig. 4c), likely due to lamin A/C aggregates both at the nuclear periphery and in the nucleoplasmic area, nuclear blebs (Fig. 4d) and complex nuclear lobulations (Fig. 4e), likely due to twisting of the nuclear envelope, in around 44% of analyzed nuclei of individual 1 (Fig. 4f). With ~90% the gross majority of these abnormalities consisted of nuclear invaginations. These nuclear abnormalities largely resemble the findings in other progeroid forms of nuclear envelopopathies (Carrero et al. 2016; Cau et al. 2014) and are in accordance with the findings in LAP1B-deficient mice (Kim et al. 2010). Additionally, comparable to the previous findings we observed in around 4% of individual 1’s primary fibroblasts nuclear holes that differed in shape and dimensions (Fig. 4g), which according to the previous data likely resemble cytoplasmic channels traversing the nucleus (Fichtman et al. 2019). Such nuclear channels were not observed in control cell lines, and we have not observed them before either in primary cell lines of unaffected or in individuals affected by various progeroid features (Hisama et al. 2011; Lessel et al. 2014b, 2017b; Marbach et al. 2019).

**Premature senescence in patient’s dermal fibroblasts**

Since lamin B1, besides being an integral part of the nuclear envelope, is a well-established marker of cellular senescence (Shimi et al. 2011) we asked whether this might point to premature senescence in fibroblasts of individual 1. We therefore analyzed by immunoblotting, the mTOR (mammalian target of rapamycin) pathway, investigating both basal and phosphorylated S6, a ribosomal protein that is phosphorylated in response to mTOR activation, in passage 7. We observed significantly elevated levels of phosphorylated S6 kinase (pS6k) in fibroblasts of individual 1 (Fig. 5a, b, Fig. S6) providing further evidence for premature senescence of these fibroblasts (Blagosklonny 2012). In addition, using the senescence-associated beta-galactosidase (SA-βgal), we confirmed the senescent state of the primary cell lines of individual 1.
This cellular phenotype rapidly advanced and his fibroblasts entered replicative senescence, e.g., stopped dividing, at passage 10. In stark contrast and as expected, control cells—managed in the same manner as individual 1’s fibroblasts—proliferated beyond passage 40. Senescence is not only a common finding in several segmental progeroid syndromes (Carrero et al. 2016; Cau et al. 2014; Eriksson et al. 2003; Salk et al. 1981; Tivey et al. 2013), but has additionally been established as one of the main hallmarks of “physiological” aging (Lopez-Otin et al. 2013). Therefore, these data further suggest the clinical diagnosis of a segmental progeroid features on the cellular level.
Abnormal activation of extracellular signal-regulated kinase (ERK1/2) in patient’s dermal fibroblasts

A common theme that has emerged amongst nuclear envelopopathies is the deregulation of the MAPK signaling pathway, and more specifically the marked activation of the ERK1/2 pathway, in several in vitro models (Muchir et al. 2007a, 2009; Tapia et al. 2015; Zhou et al. 2017). The MAPK signaling pathway is activated in Emery–Dreifuss muscular dystrophy mice models, bearing either the Lmna H222P mutation (Muchir et al. 2007b) or an EMD null allele (Muchir et al. 2007a). Moreover, in vitro down-regulation of lamin A, emerin (Muchir et al. 2009) or LEMD2 (Huber et al. 2009) resulted in activation of extracellular signal-regulated kinase (ERK1/2), similar to recent findings in SYNE1-associated diseases (Zhou et al. 2017). Activation of the MAPK signaling pathway was also observed in Lemd2-deficient mice (Tapia et al. 2015). These findings prompted us to analyze basal ERK1/2 and phosphorylated ERK1/2 levels in primary cells of individual 1 by immunoblotting. We found that in all three subsequent passages the level of phosphorylated ERK1/2 was significantly higher in individual 1’s fibroblasts as compared to fibroblasts of a healthy control (Fig. 5d, e, Fig. S7). These results further support the role of nuclear envelope proteins in the regulation of cell signaling.
Ectopic expression of wild-type TOR1AIP1 mitigates the observed cellular phenotypes

As described above, cellular characterization of primary fibroblasts derived from individual 1 revealed absent LAP1B and LAP1C, constitutively low lamin A/C levels, aberrant nuclear morphology, premature cellular and replicative senescence, and abnormal ERK1/2 activation. While neither premature senescence nor ERK1/2 levels had been analyzed in previously reported human TOR1AIP1 pathologies, one study reported mildly elevated lamin A/C levels in both skeletal and cardiac muscles (Ghaoui et al. 2016). Individuals bearing the homozygous p.(Arg321*) did not display altered lamin A/C levels (Fichtman et al. 2019). In addition, the nuclear abnormalities, although in accordance with the findings in LAP1-deficient mice (Kim et al. 2010) and being reported in human TOR1AIP1 pathologies before (Fichtman et al. 2019; Kayman-Kurekci et al. 2014), have not been observed in all individuals (Dorboz et al. 2014). To further confirm that the cellular phenotypes observed in individual 1 are caused by the TOR1AIP1 mutations and thereby to confirm their causality, we transiently transfected his fibroblasts with a plasmid containing the wild-type TOR1AIP1 open reading frame (ORF). Using polyethylenimine polyplex transfection technology (Viromer RED), we achieved a transfection efficiency of around 20% in passage 8 of individual 1’s fibroblasts, as revealed by immunofluorescence analysis with anti-FLAG (Fig. S8). Protein analysis in three subsequent fibroblast passages (P4-6), Analyses of phosphorylated ERK1/2 (p-ERK1/2) and total ERK1/2 normalized versus β-actin in individual 1’s dermal fibroblasts and a control sample. Note the increased levels of p-ERK1/2 in patient’s fibroblasts relative to control sample (d). Quantification of experiments in three subsequent fibroblast passages (P4-6), as shown in (d). Data are presented as mean±SEM. Two-tailed Student’s t test (e).
resulted in a significantly reduced rate of aberrant nuclei in individual 1’s fibroblasts as compared to non-transfected cells ($P = 0.0043$), and we observed no nuclei lacking lamin A/C staining (Fig. 6b, c). These findings strongly suggest the causal role of the $TOR1AIP1$ mutations identified in individual 1.

**Discussion**

Segmental progeroid syndromes, defined as syndromes with signs of premature aging affecting more than one tissue or organ (Martin 1978), are highly heterogenous genetic disorders. Studies utilizing next-generation sequencing (NGS) approaches have revealed several novel progeroid genes in recent years (Ehmke et al. 2017; Jay et al. 2016; Lessel et al. 2014b, 2017b, 2018; Marbach et al. 2019; Paolacci et al. 2018; Puente et al. 2011; Schrauwen et al. 2015; Wambach et al. 2018), and broadened the spectrum of phenotypes of many known progeroid conditions and the number of associated genetic causes (Lessel et al. 2014a, 2015; Rodriguez-Garcia et al. 2018; Soria-Valles et al. 2016).

Here we describe two individuals affected by multisystem anomalies and progeroid features that progressed with age, bearing compound heterozygous pathogenic variants in $TOR1AIP1$ affecting both LAP1 isoforms. Recent studies have associated biallelic $TOR1AIP1$ mutations with several conditions somewhat mimicking the clinical heterogeneity and phenotypic continuum of $LMNA$-associated disorders (Bertrand et al. 2011). Both individuals presented herein share some clinical features with the individuals affected by isolated LAP1B deficiency, i.e., a severe form of cardiomyopathy and muscular atrophy. The fulminant cardiac crisis, accompanied by kidney failure in individual 1 and death in individual 2, further highlights the importance of tight cardiac surveillance for $TOR1AIP1$ mutated individuals (Ghaoui et al. 2016). On the other hand, early onset multisystem anomalies, such as congenital hearing loss, bilateral cataracts, developmental delay, growth retardation and progressive progeroid appearance have been documented only in individuals bearing the homozygous p.(Arg321*), who have a combined LAP1B and LAP1C deficiency (Fichtman et al. 2019). Mandibular hypoplasia with dental crowding and irregular teeth, scleroderma-like skin changes, Raynaud’s phenomenon, most of which are commonly observed in other segmental progeroid syndromes (Cau et al. 2014; Lessel et al. 2015), have not been previously associated with $TOR1AIP1$ before (Table 1). It is worth noting that we cannot exclude the possibility that some of these features might have been present in previously reported individuals but were not documented. For instance, the image of the index patient reported by Kayman-Kurekci et al. shows a young woman with somewhat small mandible and gracile habitus that is not further mentioned in their manuscript (Kayman-Kurekci et al. 2014). Our findings further suggest that a combined LAP1B and LAP1C deficiency results in early onset, multisystem anomalies as compared to isolated LAP1B deficiency. However, we cannot completely exclude the possibility that any of the present or previously reported individuals (Fichtman et al. 2019) with combined LAP1B and LAP1C deficiency bears additional variant or epigenetic change in other genes that may modify the phenotype.

To gain further evidence that the $TOR1AIP1$ variants in individual 1 are causative, we performed functional characterization of patient-derived dermal fibroblasts. The paternal variant creates a frameshift 1, whereas the maternal missense
variant affects a highly conserved arginine residue. Immunoblotting revealed strongly reduced LAP1B and LAP1C transcript levels arguing that both inherited variants result in at least a strong hypomorphic allele. Moreover, we observed constitutively low lamin A/C levels in several fibroblast passages accompanied by complete loss of lamin A/C immunofluorescence staining in around 18% of the patient cells. Although LAP1 is a known interactor of lamin A/C (Kubben et al. 2010), this is in contrast to previously published data where lamin A/C levels were mildly elevated in both skeletal and cardiac muscles of a single patient (Ghaoui et al. 2016) or not altered (Fichtman et al. 2019). However, the latter study did identify reduced lamin A/C staining in individuals bearing the homozygous nonsense alteration (Fichtman et al. 2019). Furthermore, similar to the previous findings (Fichtman et al. 2019) we also observed nuclear cytoplasmic channels in primary fibroblasts of the individual 1. Further characterization of the primary fibroblasts of the individual 1 revealed that these cells prematurely enter senescence, as revealed by deregulation of LMNB1 and phosphorylated S6 kinase, positive SA-β-gal staining and early replicative senescence. To confirm that the cellular phenotypes observed in our study are indeed due to the TOR1AIP1 variants, we have over-expressed wild-type TOR1AIP1 in fibroblasts and observed a partial to complete rescue of several cellular phenotypes, thus providing strong evidence for their causality. In conclusion, using a combination of exome sequencing and segregation analyses followed by functional characterization of primary fibroblasts of individual 1, we identified biallelic pathogenic variants in TOR1AIP1 resulting in combined LAP1B and LAP1C deficiency as the genetic cause of two individuals affected by multisystem anomalies and progressive progeroid features. Thus, we further expand the clinical phenotype underlying TOR1AIP1-associated disorders and suggest that individuals bearing combined LAP1B and LAP1C deficiency can survive beyond the 1st decade of life.

Acknowledgements Open Access funding provided by Projekt DEAL. We are thankful to the affected individuals and their family members for their participation. This work was funded in part by the Deutsche Forschungsgemeinschaft (LE4223/1-1) to DL. We thank Ms. Jennifer Kaiser and Mr. Mohammad Javad Saeidi for excellent technical assistance, Dr. Julia Wickert, Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, for assistance in patient care, and Dr. Peter Bannas and the Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, for providing us the chest X-ray of individual 1. We also thank Sibley Heart Center Cardiology, Atlanta, USA, for providing us the echocardiogram of individual 2.

Data availability The identified TOR1AIP1 variants have been deposited to the Leiden Open (source) Variation Database (LOVD) (http://www.lovd.nl/3.0/home) and will be available upon manuscript acceptance. The raw whole-exome sequencing data that support the findings in affected individual cannot be made publicly available for reasons of affected individual’s confidentiality. Qualified researchers may apply for access to these data, pending institutional review board approval. All other data generated or analyzed during this study are included in this published article (and its supplemental data).

Compliance with ethical standards

Conflict of interest P Nürnberg is a founder, CEO, and shareholder of ATLAS Biolabs GmbH. ATLAS Biolabs GmbH is a service provider for genomic analyses. The other authors declare that they have no conflict of interest.

Research involving human participants The study has ongoing approval from the University Medical Center Hamburg-Eppendorf Institutional Review Board. The study was performed in accordance with the Declaration of Helsinki protocols.

Informed consent All biological samples were obtained following written informed consent from studied individuals or their legal representatives.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Agarwal AK, Fryns JP, Auchus RJ, Garg A (2003) Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Hum Mol Genet 12:1995–2001

Alastalo TP, West G, Li SP, Keinanen A, Helenius M, Tyni T, Lapatto R, Turunlahti M, Heikkila P, Kaariainen H, Laasko M, Mauermann M, Herrmann H, Pihkala J, Taimen P (2015) LMNA Mutation c.917T>G (p. L306R) leads to deleterious hyper-assembly of lamin A/C and associates with severe right ventricular cardio-myoopathy and premature aging. Hum Mutat 36:694–703. https://doi.org/10.1002/humu.22793

Bertrand AT, Chikhaoui K, Yaou RB, Bonne G (2011) Clinical and genetic heterogeneity in laminopathies. Biochem Soc Trans 39:1687–1692. https://doi.org/10.1042/BST20110670

Bione S, Maestrini E, Rivella S, Mancini M, Regis S, Romeo G, Toniolo D (1994) Identification of a novel X-linked gene responsible for Emery–Dreifuss muscular dystrophy. Nat Genet 8:323–327. https://doi.org/10.1038/ng1294-323

Blagosklonny MV (2012) Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. Aging (Albany NY) 4:159–165. https://doi.org/10.18632/aging.100443

Bonne G, Di Barletta MR, Varnous S, Becane HM, Hammouda EH, Merlini L, Muntoni F, Greenberg CR, Gary F, Urtizberea JA, Duboc D, Fardeau M, Toniolo D, Schwartz K (1999) Mutations in the gene encoding lamin A/C cause autosomal dominant
Emery–Dreifuss muscular dystrophy. Nat Genet 21:285–288. https://doi.org/10.1038/7699

Boone PM, Yuan B, Gu S, Ma Z, Gambin T, Gonzaga-Jauregui C, Jain M, Murdock TJ, White JJ, Jhangiani SN, Walker K, Wang Q, Muzny DM, Gibbs RA, Heijtmans JC, Lupsik J, Posey JE, Lewis RA (2016) Hutterite-type cataract maps to chromosome 6p21.32–p21.31, cosegregates with a homozygous mutation in LEMD2, and is associated with sudden cardiac death. Mol Genom 4:77–94. https://doi.org/10.1093/mgen/pgs3.181

Cao H, Hegele RA (2000) Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type partial lipodystrophy. Hum Mol Genet 9:109–112

Capriotti E, Fariselli P, Casadio R (2005) I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure. Nucleic Acids Res 33:W306–W310. https://doi.org/10.1093/nar/gki375

Carrero D, Soria-Valles C, Lopez-Otin C (2016) Hallmarks of progeroid syndromes: lessons from mice and reprogrammed cells. Dis Model Mech 9:719–735. https://doi.org/10.1242/dmm.024711

Chen L, Lee L, Kudlow BA, Dos Santos HG, Sletvold O, Shafeghati J, Jay AM, Conway RL, Thiffault I, Saunders C, Farrow E, Adams J, Ackerman J, Atherton J, Vidaileit H Jr, Spudich S, De Girolami U, Seidman JG, Seidman C, Muntoni F, Le Merrer M, Levy N (2003) Lamin A truncation in Hutchinson–Gilford progeria. Science 300:2055. https://doi.org/10.1126/science.1084125

Dorboz I, Coutelier M, Bertrand AT, Caberg JH, Elmaleh-Berges M, Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M,的感受性についての研究と進歩。Semin Cell Dev Biol 29:125–147. https://doi.org/10.1016/j.semcdb.2014.03.021

De Sandre-Giovannoli A, Chaouch M, Kozlov S, Vallat JM, Tazir M, De Sandre-Giovannoli A, Levy N (2014) Nuclear matrix, nuclear envelope and premature aging syndromes in a translational research perspective. Semin Cell Dev Biol 29:125–147. https://doi.org/10.1016/j.semcdb.2014.03.021

Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, Dutra A, Pak E, Durkin S, Csoka AB, Boehnke M, Glover TW, Collins FS (2003) Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome. Nature 423:293–298. https://doi.org/10.1038/nature01629

Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M, Atherton J, Vidaileit H Jr, Spudich S, De Girolami U, Seidman JG, Seidman C, Muntoni F, Muehle G, Johnson W, McDonough B (1999) Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 341:1715–1724. https://doi.org/10.1056/NEJM199912023431202

Fichtman B, Zagair F, Biran N, Barsheeshet Y, Chernysh E, Ben Neriah Z, Shaag A, Assa M, Elpeleg O, Harel A, Spiegel R (2019) Combined loss of LAP1B and LAP1C results in an early onset multisystemic nuclear envelopopathy. Nat Commun 10:605. https://doi.org/10.1038/s41467-019-08493-7

Ghaoui R, Benavides T, Lek M, Waddell LB, Kaur S, North KN, MacArthur DG, Clarke NF, Cooper ST (2016) TOR1AIP1 as a cause of cardiac failure and recessive limb-girdle muscular dystrophy. Neuromuscular Disord 26:500–503. https://doi.org/10.1016/j.nmd.2016.05.013

Gros-Louis F, Dupre N, Dion P, Fox MA, Laurent S, Verreault S, Sanes JR, Bouchard JP, Rouleau GA (2007) Mutations in SYNE1 lead to a newly discovered form of autosomal recessive cerebellar ataxia. Nat Genet 39:80–85. https://doi.org/10.1038/ng1927

Hellemans J, Lessel D, Leistritz D, Friedrich K, McBride KL, Pastore MT, Gottesman GS, Saha B, Martin GM, Kubisch C, Oshima J (2011) Coronary artery disease in a Werner syndrome-like form of progeria characterized by low levels of progerin, a splice variant of lamin A. Am J Hum Genet 15A:3002–3006. https://doi.org/10.1002/ajmg.a.34336

Hoffmann K, Dreger CK, Olins AL, Olins DE, Shultz LD, Lucke B, Karl H, Kaps R, Muller D, Vaya A, Aznar J, Ware RE, Sotelo Cruz N, Lindner TH, Herrmann H, Reis A, Sperling K (2002) Mutations in the gene encoding the lamin B receptor produce an altered nuclear morphology in granulocytes (Pelger–Huet anomaly). Nat Genet 31:410–414. https://doi.org/10.1038/ng925

Huang LT, Gromia MM, Ho SY (2017) iPTREE-STAB: interpretable decision tree based method for predicting protein stability changes upon mutations. Bioinformatics 23:1292–1293. https://doi.org/10.1093/bioinformatics/btm100

Huber MD, Guan T, Gerace L (2009) Overlapping functions of nuclear envelope proteins NET25 (Lem2) and emerin in regulation of extracellular signal-regulated kinase signaling in myoblast differentiation. Mol Cell Biol 29:5718–5728. https://doi.org/10.1128/MCB.00270-09

Jay AM, Conway RL, Thiffault I, Saunders C, Farrow E, Adams J, Toriello HV (2016) Neonatal progeroid syndrome associated with biallelic truncating variants in POLR3A. Am J Hum Genet 170:3343–3346. https://doi.org/10.1056/ajmg.a.37960

Kayman-Kurekci G, Talim B, Korkusuz P, Sayar N, Sarigolu T, Oncel I, Sharaif P, Gundesli H, Balcı-Hayta B, Purali N, Serdaroglu-Oflazer P, Topaloglu H, Dincer P (2014) Mutation in TOR1AIP1 encoding LAP1B in a form of muscular dystrophy: a novel gene related to nuclear envelopal. Neuromuscular Disord 24:624–633. https://doi.org/10.1016/j.nmd.2014.04.007

Kim CE, Perez A, Perkins G, Ellisman MH, Dauer WT (2010) A molecular mechanism underlying the neural-specific defect in torSina mutant mice. Proc Natl Acad Sci USA 107:9861–9866. https://doi.org/10.1073/pnas.0912877107

Kubben N, Voncken JW, Demmers J, Calis C, van Almen G, Pinto Y, Misteli T (2010) Identification of differential protein interactors of lamin A and progerin. Nucleus 1:513–525. https://doi.org/10.4161/nuc.1.6.13512

Lessel D, Kubisch C (2019) Hereditary syndromes with signs of premature aging. Dtsch Arztebl Int 116:489–496. https://doi.org/10.3238/arztebl.2019.0489
Lessel D, Saha B, Hisama F, Kaymakamzade B, Nurlu G, Gursoy-Ozdemir Y, Thiele H, Nurnberg P, Martin GM, Kubisch C, Oshima J (2014a) Atypical Aicardi–Goutieres syndrome: is the WNR locus a modifier? Am J Med Genet A 164A:2510–2513. https://doi.org/10.1002/ajmg.a.36664

Lessel D, Vaz B, Halder S, Lockhart PJ, Marinovic-Terzic I, Lopez-Mosqueda J, Philipp M, Sim JC, Smith KR, Oehler J, Cabrera E, Freire R, Pope K, Nahid A, Norris F, Leventer RJ, Delatycki MB, Barbi G, von Ameln S, Hogel J, Degoricija M, Fertig R, Burkhalter MD, Hofmann K, Thiele H, Altmuller J, Nurnberg G, Nurnberg P, Bahlo M, Martin GM, Aalfs CM, Oshima J, Terzic J, Amor DJ, Dikic I, Ramadhan K, Kubisch C (2014b) Mutations in SPRTN cause early onset hepatocellular carcinoma, genomic instability and progeroid features. Nat Genet 46:1239–1244. https://doi.org/10.1038/ng.3103

Lessel D, Hisama FM, Szakson K, Saha B, Sanjuanelo AB, Salbert BA, Steele PD, Baldwin J, Brown WT, Piussan C, Plauchu H, Szilvassy J, Horkay E, Hogel J, Martin GM, Herr AJ, Oshima J, Kubisch C (2015) POLD1 germine mutations in patients initially diagnosed with Werner syndrome. Hum Mutat 36:1070–1079. https://doi.org/10.1002/humu.22833

Lessel D, Schob C, Kury S, Reijnders MRF, Harel T, Eldomery MK, Marbach F, Rustad CF, Riess A, Dukic D, Hsieh TC, Jobani I, Prescott J, Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G, Grange DK, Young SG, Miner JH (2007) Increased progerin expression associated with unusual LMNA mutations causes severe progeroid syndromes. Hum Mutat 28:882–889. https://doi.org/10.1002/humu.20536

Muchir A, Bonne G, van der Kooi AJ, van Meegen M, Baas F, Bolhuis PA, de Visser M, Schwartz K (2000) Identification of mutations in the gene encoding lamin A/C in autosomal dominant limb girdle muscular dystrophy with atrophicventricular conduction disturbances (LGMD1B). Hum Mol Genet 9:1453–1459

Muchir A, Pavlidis P, Bonne G, Hayashi YK, Worman HJ (2007a) Activation of MAPK in hearts of EMD null mice: similarities between mouse models of X-linked and autosomal dominant Emery–Dreifuss muscular dystrophy. Hum Mol Genet 16:1884–1895. https://doi.org/10.1093/hmg/ddm137

Muchir A, Pavlidis P, Decostre V, Herron AJ, Arimuera T, Bonne G, Worman HJ (2007b) Activation of MAPK pathways links LMNA mutations to cardiomyopathy in Emery–Dreifuss muscular dystrophy. J Clin Invest 117:1282–1293. https://doi.org/10.1172/JCI29042

Muchir A, Wu W, Worman HJ (2009) Reduced expression of A-type lamins and emerin activates extracellular signal-regulated kinase in cultured cells. Biochim Biophys Acta 1792:75–81. https://doi.org/10.1016/j.bbapap.2008.10.012

Nagano A, Arahata K (2000) Nuclear envelope proteins and associated diseases. Curr Opin Neurol 13:533–539

Navarro CL, de Sandre-Giovannoli A, Bernard R, Boccaïo I, Boyer A, Genevieve D, Hadi-Raja B, Gaudy-Marquèze C, Smith HT, Vareses P, Faivre M, Vloeti E, Van Essen T, Flori E, Hennekam R, Beeemer FA, Lauren T, Le Merrer M, Cau P, Levy N (2004) Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify restrictive dermopa thy as a lethal neonatal laminopathy. Hum Mol Genet 13:2493–2503. https://doi.org/10.1093/hmg/ddh265

Novelli G, Muchir A, Sanguolò F, Helbing-Leclerc A, D’Apice MR, Massart C, Capon F, Sbraccia P, Federici M, Lauro R, Tudisco C, Pallotta R, Scaramo G, Dallapiccola B, Merlini L, Bonne G (2002) Mandibuloocral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. Am J Hum Genet 71:426–431. https://doi.org/10.1086/341908

Padiath QS, Saiqo K, Schifffman R, Asahara H, Yamaha T, Koeppen A, Hogan K, Ptacek LJ, Fu YH (2006) lamin B1 duplications cause autosomal dominant leukodystrophy. Nat Genet 38:1114–1123. https://doi.org/10.1038/ng1875

Pandurangan AP, Ochoa-Montano B, Ascher BB, Blundell TL (2017) SDM: a server for predicting effects of mutations on protein stability. Nucleic Acids Res 45:W229–W235. https://doi.org/10.1093/nar/gkx439

Paolacci S, Li Y, Agolini E, Bellacchio E, Arboleda-Bustos CE, Carrero D, Bertola D, Al-Gazali L, Alders M, Altmuller J, Arboleda B, Beleggia F, Bruselles A, Ciolfi A, Gillessen-Kaesbach G, Krieg T, Mohammed S, Muller C, Novelli A, Ortega J, Sandoval A, Velasco G, Yigit G, Arboleda H, Lopez-Otin C, Wollnik B, Tartaglia M, Hennekam RC (2018) Specific combinations of biallelic POLR3A variants cause Wiedemann–Rautenstrauch syndrome. J Med Genet 55:837–846. https://doi.org/10.1136/jmedgenet-2018-105528

Parthiban V, Gromiha MM, Schomburg D (2006) CUPSAT: prediction of protein stability upon point mutations. Nucleic Acids Res 34:W239–W242. https://doi.org/10.1093/nar/gkl190

Puente XS, Quispe V, Orsorio FG, Cahillas R, Cadanillas J, Fraile JM, Ordonez GR, Puente DA, Gutierrez-Fernandez A, Fanjul-Fernandez M, Levy N, Freije JM, Lopez-Otin C (2011) Exome sequencing and functional analysis identifies BANF1 mutation as the cause of a hereditary progeroid syndrome. Am J Hum Genet 88:650–656. https://doi.org/10.1016/j.ajhg.2011.04.010

Quijano-Roy S, Mbieleu B, Bonnemann CG, Jeannet PY, Colomer J, Clarke NF, Cuisset JM, Roper H, De Meirleir L, D’Amico

Springer
A, Ben Yaou R, Nascimento A, Barois A, Demay L, Bertini E, Ferreiro A, Sewry CA, Romero NB, Ryan M, Muntoni F, Guicheney P, Richard P, Bonne G, Estournet B (2008) De novo LMNA mutations cause a new form of congenital muscular dystrophy. Ann Neurol 64:177–186. https://doi.org/10.1002/ana.21417

Rodriguez-Garcia ME, Cotrina-Vinagre FJ, Cruz-Rojo J, Garzon-Lorenzo L, Carnicero-Rodriguez P, Pozo JS, Martinez-Azorin F (2018) A rare male patient with Fontaine progeroid syndrome caused by p. R217H de novo mutation in SLC25A24. Am J Med Genet A 176:2479–2486. https://doi.org/10.1002/ajmg.a.40496

Saha B, Lessel D, Hisama FM, Leistritz DF, Friedrich K, Martin GM, Kabisch C, Oshima J (2010) A novel LMNA mutation causes altered nuclear morphology and symptoms of familial partial lipodystrophy (Dunnigan Variety) with progeroid features. Mol Syndromol 1:127–132. https://doi.org/10.1159/000320166

Salk D, Bryant E, Au K, Hoehn H, Martin GM (1981) Systematic growth studies, cocultivation, and cell hybridization studies of Werner syndrome cultured skin fibroblasts. Hum Genet 58:310–316

Schrauwen I, Szelinger S, Siniard AL, Kurdoglu A, Corneveaux JJ, Malenica I, Richholt R, Van Camp G, De Both M, Swaminathan S, Turk M, Ramsey K, Craig DW, Narayanan V, Huertelman MJ (2015) A frame-shift mutation in CAV1 is associated with a severe neonatal progeroid and lipodystrophy syndrome. PLoS One 10:e0131797. https://doi.org/10.1371/journal.pone.0131797

Serrano JB, da Cruz ES0A, Rebelo S (2016) Lamina associated polypeptide 1 (LAP1) interactome and its functional features. Membranes (Basel). https://doi.org/10.3390/membranes6010008

Shimi T, Butin-Israeli V, Adam SA, Hamanaka RB, Goldman AE, Lucas CA, Shumaker DK, Kosak ST, Chandel NS, Goldman RD (2011) The role of nuclear lamin B1 in cell proliferation and senescence. Genes Dev 25:2579–2593. https://doi.org/10.1101/gad.179515.111

Soria-Valles C, Carrero D, Gabau E, Velasco G, Quesada V, Barcena C, Moens M, Fieggen K, Mohrken S, Owens M, Puente DA, Asensio O, Loisy B, Perez A, Benoit V, Wuyts W, Levy N, Hennekam RC, De Sandre-Giovannoli A, Lopez-Otin C (2016) Novel LMNA mutations cause an aggressive atypical neonatal progeria without progerin accumulation. J Med Genet. https://doi.org/10.1136/jmedgenet-2015-103695

Tapia O, Fong LG, Huber MD, Young SG, Gerace L (2015) Nuclear envelope protein Lem2 is required for mouse development and regulates MAP and AKT kinases. PLoS One 10:e0116196. https://doi.org/10.1371/journal.pone.0116196

Tivey HS, Brook AJ, Rokicki MJ, Kipling D, Davis T (2013) p38 (MAPK) stress signalling in replicative senescence in fibroblasts from progeroid and genomic instability syndromes. Biogerontology 14:47–62. https://doi.org/10.1007/s10522-012-9407-2

Wambach JA, Wegner DJ, Patni N, Kircher M, Willing MC, Baldridge D, Xing C, Agarwal AK, Vergano SAS, Patel C, Grange DK, Kenney A, Nafat T, Nickerson DA, Bamshad MJ, Cole FS, Garg A (2018) Bi-allelic POLR3A loss-of-function variants cause autosomal-recessive Wiedemann–Rautenstrauch syndrome. Am J Hum Genet 103:968–975. https://doi.org/10.1016/j.ajhg.2018.10.010

Zhang Q, Bethmann C, Worth NF, Davies JD, Wasner C, Feuer A, Ragnauth CD, Yi Q, Mellad JA, Warren DT, Wheeler MA, Ellis JA, Skeper JN, Vorgerd M, Schlotter-Weigel B, Weissberg PL, Roberts RG, Wehnert M, Shanahan CM (2007) Nesprin-1 and -2 are involved in the pathogenesis of Emery–Dreifuss muscular dystrophy and are critical for nuclear envelope integrity. Hum Mol Genet 16:2816–2833. https://doi.org/10.1093/hmg/ddm238

Zhou C, Li C, Zhou B, Sun H, Koullourou V, Holt I, Puckelwartz MJ, Warren DT, Hayward R, Lin Z, Zhang L, Morris GE, McNally EM, Shackleton S, Rao L, Shanahan CM, Zhang Q (2017) Novel nesprin-1 mutations associated with dilated cardiomyopathy cause nuclear envelope disruption and defects in myogenesis. Hum Mol Genet. https://doi.org/10.1093/hmg/ddx116

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.